Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy-Reference-Cited by-同舟云学术

Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy

Published:2014-01 Issue:1 Volume:60 Page:62-68
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Papatheodoridis George,Goulis John,Manolakopoulos Spilios,Margariti Aikaterini,Exarchos Xenofon,Kokkonis Georgios,Hadziyiannis Emilia,Papaioannou Christos,Manesis Emanuel,Pectasides Dimitrios,Akriviadis Evangelos

Publisher

Elsevier BV

Subject

Hepatology

Reference31 articles.

1. Therapeutic strategies in the management of patients with chronic hepatitis B;Papatheodoridis;Lancet Infect Dis,2008

2. Chronic hepatitis B;Lok;Hepatology,2007

3. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;European Association For The Study Of The Liver;J Hepatol,2012

4. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues;Papatheodoridis;Liver Int,2011

5. Diagnosis and management of pre-core mutant chronic hepatitis B;Papatheodoridis;J Viral Hepat,2001

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels;Diagnostics;2024-02-25

2. Long-term entecavir therapy of chronic hepatitis B in real-life setting—Importance of quantitative HBsAg level;Indian Journal of Gastroenterology;2023-12-30

3. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment;Experimental and Therapeutic Medicine;2023-11-03

4. CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy;Frontiers in Cellular and Infection Microbiology;2023-05-03

5. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN;Hepatology Communications;2023-04-26